Regeneron Pharmaceuticals (REGN) Earnings Date & Reports

Key Takeaways

• Revenue beat by a wide margin: Total revenue reached $4.29 billion in Q2 2026, up 17% year-over-year and well above the consensus estimate of approximately $3.82 billion.
• Earnings crushed expectations: Non-GAAP earnings per share (EPS) came in at $14.29, far exceeding analyst forecasts that ranged from roughly $10.00 to $10.58.
• Dupixent sets another record: Global net sales of Dupixent, recorded by partner Sanofi, surged 38% to an all-time high of $6.0 billion, surpassing the $5.34 billion consensus estimate tracked by LSEG.
• EYLEA HD and Libtayo reach new peaks: U.S. net sales of EYLEA HD rose 52% to $596 million, while Libtayo global sales climbed 30% to $489 million — both quarterly records.
• Sanofi development balance fully repaid: The company cleared its outstanding development obligations to Sanofi, a milestone expected to boost collaboration profit margins beginning in the third quarter.
• Share buybacks accelerate: Regeneron repurchased $1.2 billion in stock during Q2, bringing first-half 2026 repurchases to $2.0 billion.

Earnings Context and Why It Matters

Regeneron's second-quarter 2026 results arrived at a critical moment for the biotechnology giant. Heading into the report, investors were grappling with two competing narratives: the remarkable growth of the company's immunology and oncology franchises versus ongoing competitive pressure on the legacy EYLEA (aflibercept) eye-disease treatment. With multiple biosimilars now available in the U.S. market and Roche's Vabysmo continuing to gain share, the durability of Regeneron's ophthalmology business had become a focal point of concern. At the same time, Dupixent's expansion into new indications and the successful ramp of the higher-dose EYLEA HD formulation carried enormous weight for the investment thesis. This quarter served as a real-world test of whether the company's newer growth engines could outrun the headwinds facing its mature products — and the answer proved decisive.

Reported Results

Regeneron reported total revenues of $4.29 billion for the second quarter of 2026, representing a 16.7% increase compared to the same period in 2025. This handily exceeded Wall Street consensus estimates, which centered around $3.82 billion. On a GAAP (Generally Accepted Accounting Principles) basis, diluted EPS was $12.23, reflecting a $1.02 negative impact from acquired in-process research and development (IPR&D) charges. Non-GAAP EPS, which excludes certain non-cash and one-time items, reached $14.29 — up 11% year-over-year and roughly 35% to 40% above the analyst consensus.

The standout performer was once again Dupixent (dupilumab), the blockbuster immunology drug co-developed with Sanofi. Sanofi-recorded global net sales hit $6.0 billion, a 38% increase driven by continued demand across atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), and other approved indications. Meanwhile, EYLEA HD U.S. net sales jumped 52% to $596 million, surpassing the legacy EYLEA formulation's U.S. sales for the first time. Legacy EYLEA U.S. sales declined 45% to $412 million, pressured by biosimilar competition and the ongoing patient transition to the higher-dose version. Libtayo (cemiplimab), Regeneron's PD-1 inhibitor for advanced cancers, delivered $489 million in global net sales — a 30% increase and another quarterly record. Sanofi collaboration revenue reached an all-time high of $2.17 billion, up 50.6% from the prior-year quarter.

AI Screener

For investors seeking to uncover opportunities in the biotechnology and pharmaceutical sector, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery tool. The platform enables users to scan thousands of securities using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Whether tracking breakout candidates, identifying trending stocks, or monitoring fundamental shifts, the AI Screener helps traders and investors efficiently narrow down the market to high-conviction ideas — saving time compared to traditional manual screening methods. Explore the screener to see how AI can enhance your market research workflow.

Market Reaction and Investor Sentiment

The market responded enthusiastically to Regeneron's second-quarter report. Shares of REGN climbed approximately 6.2% during the regular trading session on July 30, closing near $738 after opening the day at $695.42. The stock had already moved roughly 5% higher in pre-market trading as the headline numbers circulated. The magnitude of the revenue and earnings beats appeared to catch the market off guard, particularly given that consensus EPS estimates had drifted lower by about 6% in the 60 days preceding the report. Analysts at RBC Capital Markets noted that the "marked commercial outperformance" — combined with the margin uplift expected from the Sanofi development balance repayment — significantly improved the outlook for the second half of the year. The upbeat reaction also reflected relief that Dupixent's growth trajectory showed no signs of deceleration despite its already massive revenue base.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape Regeneron's trajectory through the remainder of 2026 and beyond. The full repayment of the Sanofi Development Balance stands out as a near-term catalyst: starting in the third quarter, Regeneron will no longer deduct Sanofi's share of prior development costs from collaboration profits, which management indicated should meaningfully boost reported margins. The company also raised its full-year 2026 adjusted gross margin guidance on net product sales from a range of 83%–84% to 84%–85%, signaling confidence in manufacturing efficiency improvements following the temporary disruption at its Limerick, Ireland facility.

On the pipeline front, the acceptance of cemdisiran's regulatory submissions by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of generalized myasthenia gravis (gMG), a chronic autoimmune neuromuscular disorder, marks an important regulatory milestone. Investors will also monitor the early commercial launch of Lynozyfic (linvoseltamab) for relapsed or refractory multiple myeloma, which generated $11 million in its first partial quarter. Additionally, the recently announced collaboration with Telix Pharmaceuticals to co-develop next-generation radiopharmaceutical oncology therapies adds a new dimension to Regeneron's long-term pipeline strategy.

Risks remain, particularly around the legacy EYLEA franchise, where biosimilar erosion and competitive pressure from Vabysmo will likely persist. However, with Dupixent continuing to expand across indications, EYLEA HD gaining market share in retina care, and Libtayo building momentum in oncology, Regeneron enters the second half of 2026 with considerable commercial momentum and a fortified balance sheet carrying $15.1 billion in cash and marketable securities, net of debt.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations